International Society of Nephrology’s Post

With 1 in 10 people living with chronic kidney disease (CKD), it is one of the leading causes of death globally. Yet, it remains under-recognised on the global health agenda. Today, we are co-hosting a Devex -produced discussion, where leading voices will address the interconnected nature of cardiovascular, renal and metabolic diseases and tackle the need for earlier detection, diagnosis and immediate access to treatment and care for CKD. In partnership with International Society of Nephrology, Global Patient Alliance for Kidney Health and sponsored by AstraZeneca and Boehringer Ingelheim. Discover why it’s time to make the change and advocate #ForKidneyHealth. #UNGA79

🏥 Are you aware of the silent crisis affecting 1.5 billion people worldwide? Every year, liver diseases claim over 2 million lives and are responsible for 4% of all global fatalities. 🔬 The liver, our body's crucial detox engine, carries out more than 500 functions. Yet, liver health is one of the most overlooked aspects of healthcare. This oversight has devastating consequences, leading to a staggering number of deaths annually. Leading contributors to liver disease include viral hepatitis, excessive alcohol consumption, and nonalcoholic steatohepatitis. 🧪 OWL Metabolomics OWLiver test is a breakthrough in non-invasive metabolomics technology. This test is crucial for detecting non-alcoholic steatohepatitis and the early stages of liver disease, providing essential information for effective patient management. 🌐 This World Liver Day on April 19, 2024, let's shift the focus and hashtag #StepUpForLiverHealth. Join forces with us and leaders like EASL, APASL, and AASLD in our campaign to promote liver health awareness and advance global healthcare. Participate in the movement towards better liver care and help us save lives. 🩺 #WorldLiverDay#LiverHealth#Metabolomics

🏥 Are you aware of the silent crisis affecting 1.5 billion people worldwide? Every year, liver diseases claim over 2 million lives and are responsible for 4% of all global fatalities. 🔬 The liver, our body's crucial detox engine, carries out more than 500 functions. Yet, liver health is one of the most overlooked aspects of healthcare. This oversight has devastating consequences, leading to a staggering number of deaths annually. Leading contributors to liver disease include viral hepatitis, excessive alcohol consumption, and nonalcoholic steatohepatitis. 🧪 OWL Metabolomics OWLiver test is a breakthrough in non-invasive metabolomics technology. This test is crucial for detecting non-alcoholic steatohepatitis and the early stages of liver disease, providing essential information for effective patient management. 🌐 This World Liver Day on April 19, 2024, let's shift the focus and hashtag #StepUpForLiverHealth. Join forces with us and leaders like EASL, APASL, and AASLD in our campaign to promote liver health awareness and advance global healthcare. Participate in the movement towards better liver care and help us save lives. 🩺 #WorldLiverDay#LiverHealth#Metabolomics

OWL Metabolomics nail some of the #important reasons to be 1: #liveraware 2: know your #liverhealth 3: Minor #lifestyle changes to be #liverhealthy can make a great difference to #liverhealth 4: Being #luverhealthy reduces the risks and of developing #type2diabetes #CVD #cancer #liverdisease Find out your #liverhealth with Tawazun Health MyLife365.Me

Enjoy the latest edition of ISN-ACT Global Trials Focus (GTF), a monthly list identifying and summarizing recent interesting trials relevant to kidney disease. Each trial is reviewed in context and assessed for its risk of bias in key areas ➡ https://ow.ly/1vUO50TQFSW ➡️ The TOM this month goes to the NEJM PROTECTION trial. Amino Acid infusion for AKI prevention, which turned out to be more hype than hope! . ➡️ Low dose acute PD was equal to intermittent HD in terms of 28-day mortality for patients with AKI. The results were published at CJASN. This scientific resource is made available to the global kidney health community thanks to the continued support of ISN Members. Renew/join the ISN and help us advance kidney health - together ➡️ https://ow.ly/MHgA50TQFSY #ThisIsISN - Advancing kidney health worldwide. Together.

🔬 The Hidden Connection: COVID-19 and Kidney Issues! 🌡️😷 Did you know that COVID-19 can directly impact your kidneys? 🦠💔 Recent studies have revealed that the virus invades renal cells, causing acute kidney injury and complications for patients. Get the latest insights on the surprising link between COVID-19 and kidney issues in our informative article from Encyclopedia MDPI! 📚🔬 Stay informed and stay protected! 🔗 Read the full text here: https://lnkd.in/gm2Q9RNz #COVID19 #KidneyDamage #HealthResearch #MedicalScience

With World Liver Day happening on 19 April, it is important to note that as obesity rates surge across Southeast Asia and beyond, so does the prevalence of liver disease, even among non-drinkers. Non-Alcoholic Fatty Liver Disease (NAFLD) is increasingly becoming a pressing health concern. The Enhanced Liver Fibrosis (ELF™) Test developed by Siemens Healthineers is an innovative blood test that empowers patients to monitor their liver health more regularly, marking a significant advancement in the fight against NAFLD. Diagnosis lies at the heart of NAFLD care, not only for detecting its presence but also assessing its severity. However, the current landscape often sees patients with mild cases of the disease inappropriately referred to secondary care for more invasive investigations, while those undiagnosed linger in primary care until complications of cirrhosis arise. The integration of blood screenings can offer precise information on NAFLD patients, enabling timely interventions to prevent disease progression. My colleague, Aya Tan shares more in this article. https://lnkd.in/ga7D998q Embracing innovations like the ELF™ Test is pivotal in reshaping the landscape of liver disease management. #LiverHealth #Innovation #SiemensHealthineers

Today, on 14 March, we proudly support World Kidney Day, a global campaign dedicated to raising awareness of the importance of our kidneys. This year's theme focuses on the necessity of equitable access to appropriate treatment and care for people living with kidney disease, to improve their quality of life and delay the progression of the disease. Chronic kidney disease is a relentless decline in kidney function over time, stemming from various causes, some more rare than others. Among these are C3 Glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), two ultra-rare diseases, with significant unmet needs, which have a major impact on kidney function due to anomalies in the immune system. Both can present with proteinuria, haematuria and oedema and potentially lead to irreversible kidney damage and the need for permanent dialysis or kidney transplant. Sobi joins with the community to raise awareness about kidney health and partner with the rare kidney disease community in seeking innovative solutions for patients. Learn more about kidney health and the campaign https://lnkd.in/ddyBdNYx? #Sobi #RareDiseases #WorldKidneyDay

World Kidney Day: 14 March, 2024   World Kidney Day aims to raise awareness of the importance of our kidneys to our overall health and to reduce the frequency and impact of kidney disease and its associated health problems worldwide. Celebrated on the second Thursday in March, World Kidney Day pursues the following objectives: 1) Raise awareness about our "amazing kidneys" 2) Highlight that diabetes and high blood pressure are key risk factors for Chronic Kidney Disease (CKD). 3) Encourage systematic screening of all patients with diabetes and hypertension for CKD. 4) Encourage preventive behaviours. 5) Encourage transplantation as a best-outcome option for kidney failure, and the act of organ donation as a life-saving initiative. If detected early, Chronic Kidney Diseases can be treated--thereby reducing other complications and dramatically reduce the growing burden of deaths and disability from chronic renal and cardiovascular disease worldwide. CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION Manoj Vyas Dr. Sandeep Singh Jaimeen Vanparia Harakh Shah, PMP® Tapan Shah Ankit Parikh Ajit Upadhyaya Ankit Pandav Devang Pandya Udayan Vyas

In a major new study published in The Lancet, a team of researchers led by Professor Danny Gale from UCL used information from the UK National Registry of Rare Kidney Diseases (RaDaR) to show that improving treatments for rare kidney diseases could significantly decrease the need for dialysis and transplants. RaDaR is the largest rare kidney disease registry in the world and has now recruited over 30,000 patients, aged 0-96 years from 108 UK hospitals across 29 rare disease categories. Danny and the team studied kidney function decline, kidney failure, and survival in 27,285 patients with 28 categories of rare kidney diseases. They also looked at how their health compared with that of 2.81 million patients who have CKD due to other causes such as diabetes. Results showed that, over five years, people with rare kidney diseases were 28 times more likely to reach kidney failure than patients with CKD from other causes, but they were much less likely to die both during the earlier stages of CKD and whilst on dialysis. Read the full article and findings by clicking the link below 👇 https://bit.ly/4ccnv2f #KidneyDisease #Kidney #KidneyHealth #TeamKidney #KidneyAwareness #NewResearch